1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 20 JULY 2015

Cancer Drug News 20 JULY 2015

  • July 2015
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Immunocore's Future Looks Bright
Industry Trend Analysis - Positive Phase II Blincyto Data Will Secure Second FDA Nod
Industry Brief - Celator Begins CPX-351 Phase II Trial In AML Patients At High Risk For Induction Mortality
Industry Trend Analysis - Ixazomib Will Gain Swift Approval In US
Industry Brief - Cleave's CB-5083 Gains FDA ODD For MM
Industry Brief - Argos Completes Enrolment In AGS-003 Phase III Trial In MRCC
Industry Trend Analysis - Exelixis Will Finally See Success With Cabozantinib
Industry Brief - Cellceutix' Kevetrin Gains FDA ODD For OC
Industry Brief - Immunovaccine's DPX-Survivac Gains FDA ODD For OC
Industry Brief - DSMB Recommends Continuation Per Protocol Of Genticel's GTL001 Phase II Trial
Industry Trend Analysis - EMA's HPV Vaccine Safety Review Will Have Little Impact On Sales
Industry Brief - Delcath Receives FDA ODD For Melphalan In Cholangiocarcinoma
Industry Brief - Kowa/Chugai Sign Japanese Peretinoin Licensing Deal For HCC
Industry Brief - Apogenix/CANbridge Sign APG101 Licensing Deal In China
Industry Brief - RedHill Extends Option Agreement For RP101 Acquisition
Industry Brief - Agenus Acquires CEACAM1 Antibodies From Diatheva
Industry Brief - Hikma Gains US Thiotepa sANDA Approval
Industry Brief - Sanofi To Reorganise Business Structure
Industry Brief - Sorrento/NantBioScience Form JV To Develop Small Molecule Therapies Against Cancer
Industry Brief - Cancer Conferences - October 2015

Table Of Contents

Cancer Drug News 20 JULY 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by GlobalData

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

  • $ 6400
  • Industry report
  • February 2017
  • by Venture Planning Group

Complete report $9,800.  DataPack (test volumes, sales forecasts, supplier shares) $6,400. Highlights Comprehensive 620-page analysis of the US tumor marker testing market.Major issues pertaining to the ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.